Список литературы

81. Scully M., McDonald V., Cavenagh J., et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53. DOI:10.1182/BLOOD-2011-03-341131.

82. Chemnitz J., Draube A., Scheid C., et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71(2):105–8. DOI:10.1002/AJH.10204.

83. Froissart A., Buffet M., Veyradier A., et al. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104–11. DOI:10.1097/CCM.0B013E31822E9D66.

84. Scully M., Cohen H., Cavenagh J., et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. DOI:10.1111/J.1365-2141.2006.06448.X.

85. Jestin M., Center on behalf of the F.T.M.R., Benhamou Y., et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2018;132(20):2143–53. DOI:10.1182/BLOOD-2018-04-840090.

86. Upreti H., Kasmani J., Dane K., et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037–45. DOI:10.1182/BLOOD.2019001056.

87. Scully M., Thomas M., Underwood M., et al. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014;124(2):211–9. DOI:10.1182/BLOOD-2014-02-553131.

88. Cataland S.R., Jin M., Lin S., et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol. 2007;139(3):486–93. DOI:10.1111/J.1365-2141.2007.06819.X.

89. Patriquin C.J., Thomas M.R., Dutt T., et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol. 2016;173(5):779–85. DOI:10.1111/BJH.13993.

90. Maschan A., Petrova U., Kalinina I., et al. Bortezomib induces long-term remission in children with immune thrombotic thrombocytopenic purpura, refractory to plasma exchange, glucocorticoids, and rituximab: A report on two cases. Pediatr blood & cancer. 2021;68(4):e28818. DOI:10.1002/PBC.28818.

91. Pasquale D., Vidhya R., Dasilva K., et al. Chronic Relapsing Thrombotic Thrombocytopenic Purpura: Role of Therapy With Cyclosporine. J Hematol. 1998;57:57–61. DOI:10.1002/(SICI)1096-8652(199801)57:1.

92. Subklewe M., Sebelin-Wulf K., Beier C., et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol. 2007;68(3):147–55. DOI:10.1016/J.HUMIMM.2006.12.005.

93. Kappers-Klunne M.C., Wijermans P., Fijnheer R., et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130(5):768–76. DOI:10.1111/J.1365-2141.2005.05681.X.

94. Dubois L., Gray D.K. Splenectomy: Does it still play a role in the management of thrombotic thrombocytopenic purpura? Can J Surg. 2010;53(5):349.

95. Rutkow I.M. Thrombotic thrombocytopenic purpura (TTP) and splenectomy: a current appraisal. Ann Surg. 1978;188(5):701–5. DOI:10.1097/00000658-197811000-00021.

96. Veltman G.A.M., Brand A., Leeksma O.C., et al. The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura. Ann Hematol. 1995;70(5):231–6. DOI:10.1007/BF01784041.

97. Аксельрод Б.А., Балашова Е.Н., Баутин А.Е., et al. Клиническое использование эритроцитсодержащих компонентов донорской крови. Гематология и трансфузиология. 2018;63(4):372–435. DOI:10.25837/HAT.2019.62.39.006.

98. Benhamou Y., Baudel J.L., Wynckel A., et al. Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center. Am J Hematol. 2015;90(6):E127–9. DOI:10.1002/AJH.23997.

99. Bobbio-Pallavicini E., Gugliotta L., Centurioni R., et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997;82(4):429–35.

100. Момот А.П., Молчанова И.В., Батрак Т.А. Референтные значения показателей системы гемостаза при физиологически протекающей беременности и после родоразрешения. Проблемы репродукции. 2015;21(1):89–97. DOI:10.17116/repro20152189-97.

101. Sánchez-Luceros A., Farías C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost. 2004;92(6):1320–6. DOI:10.1160/TH03-11-0683.

102. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001;98(9):2730–5. DOI:10.1182/BLOOD.V98.9.2730.

103. Roose E., Tersteeg C., Demeersseman R., et al. Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of Pregnancy-Onset Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open Companion J to Thromb Haemost. 2018;2(1):e8. DOI:10.1055/S-0037-1615252.

104. Ferrari B., Maino A., Lotta L.A., et al. Pregnancy complications in acquired thrombotic thrombocytopenic purpura: a case-control study. Orph J Rare Dis. 2014;9:193. DOI:10.1186/s13023-014-0193-6.

105. Jiang Y., McIntosh J.J., Reese J.A., et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014;123(11):1674–80. DOI:10.1182/BLOOD-2013-11-538900.

106. Gupta M., Feinberg B.B., Burwick R.M. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens. 2018;12:29–34. DOI:10.1016/J.PREGHY.2018.02.007.

107. Savignano C., Rinaldi C., De Angelis V. Pregnancy associated thrombotic thrombocytopenic purpura: Practical issues for patient management. Transfus Apher Sci. 2015;53(3):262–8. DOI:10.1016/J.TRANSCI.2015.11.005.

108. Fakhouri F., Scully M., Provot F., et al. Management of thrombotic microangiopathy in pregnancy and postpartum: Report from an international working group. Blood. 2020;136(19):2103–17. DOI:10.1182/BLOOD.2020005221.

109. Gangaraju R., Rodgers G.M. Upshaw-Schulman syndrome and pregnancy: successful management with plasma infusions. Ann Hematol. 2016;95(10):1745–6. DOI:10.1007/S00277-016-2755-2.

110. Ferrari B., Peyvandi F. How I treat thrombotic thrombocytopenic purpura in pregnancy. Blood. 2020;136(19):2125–32. DOI:10.1182/BLOOD.2019000962.

111. Coppo P., Schwarzinger M., Buffet M., et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience. PLoS One. 2010;5(4):e1028. DOI:10.1371/journal.pone.0010208.

112. Bendapudi P.K., Hurwitz S., Fry A., et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157–64. DOI:10.1016/S2352-3026(17)30026-1.